Cancer immunotherapies have now revolutionized into one of the promising clinical strategies for the treatment of cancers. T cells is a critical population of immune cells in the tumor microenvironment (TME) to fight cancer cells and determine the success of T cell-based immunotherapies, including immune checkpoint blockade, adoptive cellular therapies, cancer vaccines, and oncolytic virus therapy. However, response rate, adverse effects, and drug resistance of current T cell-based immunotherapies remain the main challenges for expanding their clinical applicability. Current studies indicate that these clinical challenges are due to the immunosuppressive TME inducing T cell dysfunction or blocking T cell infiltration into tumor. Moreover, the factors of the amount, subtypes, and fate of T cells regulated by tumor microenvironment also contribute to anticancer responses. Therefore, a better understanding of the crosstalk between the TME and T cell biology can fill the current unmet need for T cell-based immunotherapies, improving survival and the quality of cancer patients’ life.
In this Research Topic, we aim to present studies focusing on uncovering novel intrinsic or extrinsic factors of T cell dysfunction in the tumor microenvironment or any other novel mechanisms/strategies which can guide T cell-based immunotherapies. We welcome submissions of original research articles and reviews on all aspects related to the treatment of T cells in anticancer immunity. Relevant subtopics include but are not limited to:
• T cell-mediated antitumor immunity
• T cell dysfunction by cancer
• The metabolism of T cells in the tumor microenvironment
• The subsets of T cells in cancer immunity
• The role of T cells in cancer immune checkpoint blockade
• Adoptive T-cell immunotherapy in cancer
• The crosstalk of T cells in the tumor microenvironment
• The role of stem-like T cells in cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Cancer immunotherapies have now revolutionized into one of the promising clinical strategies for the treatment of cancers. T cells is a critical population of immune cells in the tumor microenvironment (TME) to fight cancer cells and determine the success of T cell-based immunotherapies, including immune checkpoint blockade, adoptive cellular therapies, cancer vaccines, and oncolytic virus therapy. However, response rate, adverse effects, and drug resistance of current T cell-based immunotherapies remain the main challenges for expanding their clinical applicability. Current studies indicate that these clinical challenges are due to the immunosuppressive TME inducing T cell dysfunction or blocking T cell infiltration into tumor. Moreover, the factors of the amount, subtypes, and fate of T cells regulated by tumor microenvironment also contribute to anticancer responses. Therefore, a better understanding of the crosstalk between the TME and T cell biology can fill the current unmet need for T cell-based immunotherapies, improving survival and the quality of cancer patients’ life.
In this Research Topic, we aim to present studies focusing on uncovering novel intrinsic or extrinsic factors of T cell dysfunction in the tumor microenvironment or any other novel mechanisms/strategies which can guide T cell-based immunotherapies. We welcome submissions of original research articles and reviews on all aspects related to the treatment of T cells in anticancer immunity. Relevant subtopics include but are not limited to:
• T cell-mediated antitumor immunity
• T cell dysfunction by cancer
• The metabolism of T cells in the tumor microenvironment
• The subsets of T cells in cancer immunity
• The role of T cells in cancer immune checkpoint blockade
• Adoptive T-cell immunotherapy in cancer
• The crosstalk of T cells in the tumor microenvironment
• The role of stem-like T cells in cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
